Please assess the completion status of the following clinical trial:

Trial Title: Switchover Trial From Imiglucerase to Plant Cell Expressed Recombinant Human Glucocerebrosidase

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females, 2 years or older~* Confirmed diagnosis of Gaucher disease by the enzymatic activity assay~* Stable Gaucher disease~* Treatment with imiglucerase (Cerezyme®) for at least 2 years and on a stable maintenance regimen (dose and regimen unchanged, except for situation of drug shortage) for at least the last six months~* Able to provide written informed consent~Exclusion Criteria:~* Currently taking another experimental drug for any condition~* History of allergy to carrots~* History of allergy to beta lactam antibiotics~* Previous infusion reaction suspected to be allergic in nature to Cerezyme® or Ceredase® or receiving premedication to prevent infusion reactions~* Presence of HIV and/or HBsAg and/or hepatitis C infection~* Presence of unresolved anemia due to iron, folic acid or vitamin B12 deficiency~* Presence of any significant comorbidity that could confound the interpretation of the clinical response to taliglucerase alfa~* Presence of any medical, emotional, behavioral or psychological condition that in the judgment of the Investigator would interfere with the patient's compliance with the requirements of the study

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Taliglucerase alfa (Type: EXPERIMENTAL): Open label taliglucerase alfa treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).